Pharma Tech Outlook: Pharma Tech Magazine

BennuBio: A Potential Breakthrough in Cellular Analysis

Top 10 Drug Discovery and Development Consulting/Service Companies - 2020


Over the past 100 years, drugs discovered by the pharmaceutical industry have drastically changed the practice of medicine and impacted several aspects of society. Drug discovery was always based on ethnobotanical knowledge with a target and mechanism-agnostic approach. However, today, with the advent of modern molecular biology methods and a better understanding of the human genome, drug discovery has changed into a hypothesis-driven target-based approach.

Evidently, this has made laboratories highly-computerized and automated, where pharma companies are actively using AI solutions to kick-start the entire R&D process. AI can reduce timelines of drug discovery and improve the agility of the research process, increase the accuracy of predictions on the efficacy and safety of drugs, and improve the opportunity to diversify drug pipelines.

In the past few years, a majority of pharma companies have started adopting various strategies to actively integrate AI into their drug discovery process by hiring AI experts and data analysts. A part of their strategy also includes investing in startups and collaborating with tech giants, and research centers. While it is too early to conclude which strategy will be more successful, organizations are adding an addendum to this strategy by adopting more than one AI solution at different stages of the drug discovery process and collaborating with several companies at a time. To stay competitive in the increasingly sophisticated technologies and an unstable economic environment, biopharma companies are also increasingly outsourcing research activities to contract research organizations (CROs). Several pharma companies are also implementing machine learning-based deep learning technology to transform the small molecule research field and identify new biologics such as therapeutic antibodies against cancer, fibrosis, and other diseases—this approach has reduced the time-to-market of the antibody therapeutics by 3-18 months.

At this juncture, many cutting-edge drug development solution providers and consulting companies are entering the domain with advanced and integrated offerings. To help the pharmaceutical sector strengthen its operational capabilities and simultaneously enable growth in the industry, Pharma Tech Outlook has compiled this edition. The list comprises prominent organizations in the industry that address issues pertinent to drug development by implementing current trends. Besides, the magazine also includes insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CXOs. We present to you Pharma Tech Outlook’s, “Top 10 Drug Discovery and Development Consulting/Service Companies – 2020.”

    Drug Discovery and Development Consulting/Service Companies

  • Sirona Dx is a technical CRO that is bridging silos between diagnostics manufacturers and translational clinical research, thereby accelerating the pace of immunotherapy and targeted therapy development. Be it for exploratory testing and biomarker development, or clinical trials and companion diagnostics, Sirona Dx offers the latest technologies and guides clients to the assays and platforms that best match their requirements. What differentiates the company from other players is its deep relationships with leading life science tools and platform providers which allows pharma clients to access cutting-edge technologies even before they are commercially available

  • As an advanced and cost-effective DNA solution provider, the company has synthesized probes used for nucleic acid detection kits, DNA and RNA for vaccine discovery, and targeting proteins for antibody discovery during the pandemic. In addition, they have also developed a silicon-based de novo antibody discovery platform, which facilitates the process of designing an antibody to any target. What differentiates Synbio Technologies is its never-ending focus on better serving the scientific communities across the globe. The company performs every operation with utmost precision and care for its clients

  • Bioduro


    From target identification to lead optimization and candidate selection, BioDuro provides a broad range of discovery services with expertise and experience. Our extensive capabilities support stand alone and integrated services in Chemistry, Biology, DMPK and Pharmacology

  • Celerion


    Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 40 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings

  • HiFiBiO Therapeutics

    HiFiBiO Therapeutics

    HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. We integrate deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders

  • ICON plc

    ICON plc

    Since the foundation of ICON plc in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 37 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas

  • IDEAYA Biosciences

    IDEAYA Biosciences

    IDEAYA is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies we are developing. We are applying these capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality – which represents an emerging class of precision medicine targets. We believe this diversified approach will enable us to deliver the right medicine to the right patient to drive a more robust clinical response. IDEAYA, headquartered in South San Francisco, California, has assembled leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology and clinical development

  • Sumitomo Dainippon Pharma Oncology

    Sumitomo Dainippon Pharma Oncology

    Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit, will collectively be known as Sumitomo Dainippon Pharma Oncology or SDP Oncology. SDP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer. At SDP Oncology, we are relentlessly exploring novel and unique approaches to address unmet needs in oncology research and development. Through scientific persistence and a commitment to discovery, we are focused on advancing a diverse and purposeful pipeline

  • Syner-G Pharma Consulting

    Syner-G Pharma Consulting

    Syner-G Pharma CMC Consulting, LLC is a Boston based consulting firm specializing in providing full spectrum of customized CMC Regulatory, Project Management and QA/cGMP services for Bio-Pharmaceutical companies. At Syner-G Pharma Consulting, Chemistry, Manufacturing and Controls (CMC) is our sole focus. We offer a complete suite of CMC solutions (CMC-360) in the following three core areas: Regulatory Affairs, Pharmaceutical Development, and QA/cGMP Compliance

  • Target RWE

    Target RWE

    Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care. Target RWE’s proven real-world data (RWD) solutions are utilized throughout the drug development and commercialization spectrum. With high-quality and comprehensive fit-for-use datasets captured across a broad range of chronic illnesses, TARGET is well-positioned to support pharmaceutical, life sciences, industry and healthcare partners with their RWE initiatives and programs